PH12018500579A1 - Fungal keratitis prophylactic or therapeutic agent - Google Patents

Fungal keratitis prophylactic or therapeutic agent

Info

Publication number
PH12018500579A1
PH12018500579A1 PH12018500579A PH12018500579A PH12018500579A1 PH 12018500579 A1 PH12018500579 A1 PH 12018500579A1 PH 12018500579 A PH12018500579 A PH 12018500579A PH 12018500579 A PH12018500579 A PH 12018500579A PH 12018500579 A1 PH12018500579 A1 PH 12018500579A1
Authority
PH
Philippines
Prior art keywords
prophylactic
therapeutic agent
fungal keratitis
keratitis
fungal
Prior art date
Application number
PH12018500579A
Other languages
English (en)
Inventor
Jinzhong Zhang
Masaaki Kageyama
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PH12018500579A1 publication Critical patent/PH12018500579A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PH12018500579A 2015-09-18 2018-03-16 Fungal keratitis prophylactic or therapeutic agent PH12018500579A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220847P 2015-09-18 2015-09-18
PCT/JP2016/077014 WO2017047597A1 (ja) 2015-09-18 2016-09-13 角膜真菌症の予防または治療剤

Publications (1)

Publication Number Publication Date
PH12018500579A1 true PH12018500579A1 (en) 2018-09-10

Family

ID=58288799

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018500579A PH12018500579A1 (en) 2015-09-18 2018-03-16 Fungal keratitis prophylactic or therapeutic agent

Country Status (13)

Country Link
US (1) US10166217B2 (cg-RX-API-DMAC7.html)
EP (1) EP3351244A4 (cg-RX-API-DMAC7.html)
JP (1) JP6639364B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180053340A (cg-RX-API-DMAC7.html)
CN (1) CN108025000A (cg-RX-API-DMAC7.html)
BR (1) BR112018005305A2 (cg-RX-API-DMAC7.html)
HK (2) HK1256969A1 (cg-RX-API-DMAC7.html)
MX (1) MX393608B (cg-RX-API-DMAC7.html)
MY (1) MY183906A (cg-RX-API-DMAC7.html)
PH (1) PH12018500579A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201802091RA (cg-RX-API-DMAC7.html)
TW (1) TWI721015B (cg-RX-API-DMAC7.html)
WO (1) WO2017047597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112957321B (zh) * 2021-03-04 2022-08-05 青岛大学附属医院 一种氧化硫酸软骨素改性的那他霉素滴眼液及其制备方法
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
EP2187743B1 (en) * 2007-08-16 2014-07-30 Santen Pharmaceutical Co., Ltd Rapamycin formulations for treatment of age related macular degeneration

Also Published As

Publication number Publication date
BR112018005305A2 (pt) 2018-10-09
HK1253545A1 (zh) 2019-06-21
EP3351244A1 (en) 2018-07-25
JP2017057199A (ja) 2017-03-23
KR20180053340A (ko) 2018-05-21
MY183906A (en) 2021-03-17
WO2017047597A1 (ja) 2017-03-23
MX393608B (es) 2025-03-24
EP3351244A4 (en) 2019-05-01
TWI721015B (zh) 2021-03-11
CN108025000A (zh) 2018-05-11
SG11201802091RA (en) 2018-04-27
US20180271841A1 (en) 2018-09-27
MX2018003381A (es) 2018-08-15
HK1256969A1 (en) 2019-10-04
US10166217B2 (en) 2019-01-01
TW201717943A (zh) 2017-06-01
JP6639364B2 (ja) 2020-02-05

Similar Documents

Publication Publication Date Title
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
CA2956871C (en) Compounds active towards bromodomains
ZA201708692B (en) Antibacterial compounds
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MY195009A (en) Cellular Targeted Active Ingredient Delivery System
PH12016501702A1 (en) Pyrazole amide derivative
NZ725399A (en) Macrocylic pyrimidine derivatives
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
MX2020012989A (es) Agente terapeutico para la fibrosis.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EA201691741A1 (ru) Фармацевтическая композиция
MX383940B (es) Formulación farmacéutica que contiene tocol fosfato.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
MX393608B (es) Profilactico o agente terapeutico para queratitis fungica.
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
MD20160040A2 (ro) Pidotimod pentru utilizare în tratamentul bolilor asociate cu inflamaţie
EA201791483A1 (ru) Фармацевтическая композиция для лечения микоза
PH12017501982A1 (en) Pharmaceutical compound
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
IN2014MU01326A (cg-RX-API-DMAC7.html)
HK40015879A (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient